Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR Special Focus

Phase I Clinical Trials: Overcoming Barriers

Susan E. Bates
Susan E. Bates
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-10-0261 Published March 2010
  • Article
  • Info & Metrics
  • PDF
Loading

A medical student, upon hearing an explanation of a phase I clinical trial, remarked that the first patients to enroll in first-in-human phase I trials were, in effect, “jumping on the grenade” for those who would come later. There are more drugs in development for cancer indications than ever before—861 according to the Pharmaceutical Research and Manufacturers of America—yet, our ability to carry out phase I trials is increasingly constrained. This issue of CCR Focus is dedicated to those patients who, for every drug currently on the market, have jumped on the grenade. Multiple factors have coalesced to increase barriers to effectively test all of these agents. The need for extensive preclinical testing, outlined by Senderowicz, is the first daunting task. Next, the nature of the phase I trial itself, and concerns about subtherapeutic dosing, leads patients and their oncologists to delay enrollment in phase I trials. Exacerbating this, as detailed by Ivy and coauthors, the community has failed to embrace novel, more efficient trial designs that might get to effective doses faster, in favor of the traditional 3 + 3 cohort design. Further, we are victims of our own success: in bringing new therapies to market, we have increased the number of salvage options, again reducing enrollment in clinical trials. The complexities of selecting patient populations who are most likely to benefit from a new agent—personalized medicine—also limit our ability to effectively execute phase I studies. Dancey and colleagues provide some guidance in this area. To help in the steadily growing regulatory burden for data collection and reporting, Rock and colleagues have outlined critical data collection components, providing in essence a Good Clinical Practice primer for the academic oncologist. Of course, these issues are not unique to drug development in the United States, as well documented in Calvert's European/Asian perspective. We have the pipeline. What we don't have are fast, straightforward methods of getting the drugs through the critical path to market and also personalizing what novel drug is best suited for a specific patient. In the following pages, Guest Editors LoRusso and Seymour have brought forward an important collection of articles. Along with guidelines generated by the National Cancer Institute Investigational Drug Steering Committee's working groups to improve and speed both phase I and II trials, they offer the researchers' own insights into, and ways of managing, the obstacles that impede our progress in this area that is so critical to our collective enterprise. As always, we hope that this issue of CCR Focus will challenge those expert in the field and prove valuable to the interested nonexpert.

    PreviousNext
    Back to top
    Clinical Cancer Research: 16 (6)
    March 2010
    Volume 16, Issue 6
    • Table of Contents
    • Table of Contents (PDF)
    • About the Cover

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Clinical Cancer Research article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Phase I Clinical Trials: Overcoming Barriers
    (Your Name) has forwarded a page to you from Clinical Cancer Research
    (Your Name) thought you would be interested in this article in Clinical Cancer Research.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Phase I Clinical Trials: Overcoming Barriers
    Susan E. Bates
    Clin Cancer Res March 15 2010 (16) (6) 1709; DOI: 10.1158/1078-0432.CCR-10-0261

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Phase I Clinical Trials: Overcoming Barriers
    Susan E. Bates
    Clin Cancer Res March 15 2010 (16) (6) 1709; DOI: 10.1158/1078-0432.CCR-10-0261
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Overview of Phase I Study Design
    • Data Needed for IND Submission
    Show more CCR Special Focus
    • Home
    • Alerts
    • Feedback
    • Privacy Policy
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians

    About Clinical Cancer Research

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2021 by the American Association for Cancer Research.

    Clinical Cancer Research
    eISSN: 1557-3265
    ISSN: 1078-0432

    Advertisement